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OBJECTIVES Because the endothelium is a major target for inflammatory cytokines, we investigated
whether elevated interleukin (IL)-10 serum levels are associated with improved endothelial
vasoreactivity in patients with coronary artery disease (CAD).
BACKGROUND Chronic inflammation plays a pivotal role in the progression of atherosclerosis. Interleukin-10
is an anti-inflammatory cytokine that exerts important protective effects on atherosclerotic
lesion development in experimental animals.
METHODS Vasoreactivity was assessed in 65 male patients with documented CAD by measuring
endothelium-dependent (acetylcholine [ACh] 10 to 50 g/min) and endothelium-
independent (sodium nitroprusside [SNP] 2 to 8 g/min) forearm blood flow (FBF)
responses using venous occlusion plethysmography.
RESULTS Serum levels of IL-10 were significantly correlated with ACh-induced FBF responses (r 
0.31, p  0.02), but not with SNP responses. Importantly, if IL-10 serum levels were
increased in patients with elevated C-reactive protein (CRP) levels, no impairment of
ACh-stimulated FBF response was observed. On multivariate analysis, including low-density
lipoprotein cholesterol, smoking, hypertension, diabetes, clinical status of the patients, and
statin and/or angiotensin-converting enzyme inhibitor treatment, only IL-10 (p  0.02) and
CRP serum levels (p  0.02) were significant independent predictors of ACh-induced FBF
responses.
CONCLUSIONS Thus, increased IL-10 serum levels are associated with improved systemic endothelial
vasoreactivity in patients with elevated CRP serum levels, demonstrating that the balance
between pro- and anti-inflammatory mediators is a major determinant of endothelial function




















Ptherosclerosis is currently regarded as a chronic inflamma-
ory disease of the vascular wall (1). Systemic markers of
nflammation have been shown to be of significant prog-
ostic relevance for assessing the risk of atherosclerotic
isease progression (2). Specifically, serum levels of the
cute-phase reactant C-reactive protein (CRP) provide
See page 50
mportant information for risk assessment in healthy volun-
eers, patients at risk, as well as patients with established
oronary artery disease (CAD) (3,4). However, data are
parse with respect to the clinical relevance of anti-
nflammatory mediators to modulate inflammatory pro-
esses of the vascular wall and disease progression. In a
ecent study, we could demonstrate that elevated serum
evels of the anti-inflammatory cytokine interleukin (IL)-10
re not only predictive of a better clinical outcome after
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ncreased risk associated with elevated CRP serum levels
5).
The vascular endothelium is a major target for inflam-
atory mediators. Indeed, elevated CRP levels are associ-
ted with impaired endothelial vasodilator function of both
he coronary and systemic circulation (6,7). Moreover,
mpaired endothelial function not only correlates with the
resence of classic risk factors for CAD (8), but also is
redictive of future cardiovascular events in patients at risk
9–14). Experimentally, IL-10 was shown to protect endo-
helial function after an acute inflammatory stimulus by
imiting increases in superoxide generation within the vas-
ular wall (15). Therefore, the present study was designed to
est the hypothesis that elevated serum levels of the anti-
nflammatory cytokine IL-10 are associated with enhanced
ndothelial vasodilator function and may counteract the
mpairment in endothelial function associated with elevated
RP serum levels in patients with established CAD.
ETHODS
atients. A total of 65 male patients were recruited from
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July 7, 2004:44–9 IL-10 and Endothelial Functioniography or interventional procedures during ACS. Be-
ause vascular reactivity and inflammatory markers may vary
ith sex hormone fluctuations, female patients were ex-
luded from the study. Forty-nine patients had stable CAD
or at least three months before forearm blood flow (FBF)
easurements. Sixteen patients were studied within five
ays (4.8  1.9 days) of an episode of unstable angina
Braunwald class IIIb), defined as angina at rest with
T-segment alterations. The presence of CAD in patients
ith stable CAD, as well as identification of the culprit
esion in patients with unstable CAD, was documented by
oronary angiography. Echocardiography was performed in
ll patients in order to exclude patients with an impaired left
entricular ejection fraction (50%). Because myocardial
ecrosis may induce an increase in CRP serum levels
nrelated to vascular inflammation, patients with troponin
levels 0.2 ng/ml were excluded. In addition, patients
ith any evidence of inflammatory or malignant diseases
ere excluded. Screening tests were performed by evalua-
ion of the patients’ history and white blood cell count, and,
f required, a urinary test or chest X-ray was performed. All
atients were taking long-term aspirin (100 mg/day) and
eta-blocker therapy. For FBF measurements, vasoactive
edications, such as calcium channel blockers, angiotensin-
onverting enzyme (ACE) inhibitors, and long-acting ni-
rates, were withheld for at least 24 h before the study,
hereas aspirin, beta-blockers, and statins were not
iscontinued.
The clinical characteristics of the patient population are
ummarized in Table 1. Of the eight patients with diabetes,
hree were treated with insulin and five received oral
ntidiabetic agents. There were no significant differences in
edical treatment between patients with stable and those
ith unstable CAD.
The study protocol had been approved by the ethics
ommittee of the J. W. Goethe University. All patients gave
ritten, informed consent.
tudy protocol. The FBF measurements were performed
s previously described (7). In brief, FBF measurements
ere performed in the morning in a quiet, temperature-
ontrolled room at 22°C (72°F). Patients were asked to
efrain from drinking alcohol or caffeine and from smoking
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACh  acetylcholine
ACS  acute coronary syndrome
CAD  coronary artery disease
CRP  C-reactive protein
FBF  forearm blood flow
HDL  high-density lipoprotein
IL  interleukin
LDL  low-density lipoprotein
NO(S)  nitric oxide (synthase)
SNP  sodium nitroprussideor 12 h before the examination. Under local anesthesia p1.5 ml of 2% mepivacaine; Astra Pharmaceuticals) and
terile conditions, a 22-gauge catheter (Braun-Melsungen,
ermany) was inserted into the brachial artery of the
ondominant arm (left in most cases) for the infusion of
rugs or saline. This arm was elevated above the level of the
ight atrium. All patients were allowed to rest for 20 min
fter catheter placement to achieve stable baseline measure-
ents before data collection. Forearm blood flow (ml/min
er 100 ml forearm tissue) was measured by venous occlu-
ion plethysmography (model EC-4; D. E. Hokanson,
ellevue, Washington) with calibrated mercury-in-Silastic
train gauges applied to the widest part of the forearm.
pper arm cuffs were intermittently inflated to 40 mm Hg
or 10 s every 15 s to temporarily prevent venous outflow
Rapid cuff inflator E-10; D. E. Hokanson). To exclude
and circulation from the blood flow, a wrist cuff was
nflated to suprasystolic pressure. Drug infusions were
dministered with a constant-rate infusion pump (Braun-
elsungen). Basal measurements were obtained after intra-
rterial sodium chloride (0.9%) infusion (rate of 1 ml/min).
or the assessment of endothelium-dependent vasodilation,
cetylcholine (Ach) (Ciba Vision GmbH, Aschaffenburg,
ermany) was infused intra-arterially in increasing dosages
f 10 to 50 g/min, with infusion rates of 0.8 to 1.2 ml/min.
odium nitroprusside (SNP) (Schwarz Pharma, Monheim,
ermany) was infused for assessment of endothelium-
ndependent vasodilation in increasing dosages of 2 to 8
g/min, with infusion rates of 0.8 to 1.2 ml/min. Each dose
as infused for 5 min, and FBF was measured during the
ast 2 min of the infusion. Each FBF determination con-
isted of at least three separate measurements at 15-s
ntervals. Analysis of the plethysmographic recordings was
able 1. Baseline Clinical Characteristics of the Study
opulation (n  65)
Characteristics
ge (yrs) 53.8  4.8
otal serum cholesterol (mg/dl) 195.2  44.1
DL cholesterol (mg/dl) 119.5  38.4
DL cholesterol (mg/dl) 48.2  14.5
ean arterial BP (mm Hg) 93.6  14.7
iabetes mellitus 8 (12%)
urrent smoking 17 (26%)
ypertension 29 (44%)
nstable angina 16 (25%)
L-10 serum levels (pg/ml) 2.4  2.1





ACE inhibitors 37 (57%)
Statins 53 (82%)
Calcium channel blocker 2 (3%)
ata are presented as the mean value  SD or number (%) of patients.
ACE angiotensin-converting enzyme; BP blood pressure; CRP C-reactive
rotein; HDL  high-density lipoprotein; IL  interleukin; LDL  low-density
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IL-10 and Endothelial Function July 7, 2004:44–9as unaware of the patients’ IL-10 and CRP levels, which
ere analyzed from blood drawings taken immediately
efore the FBF measurements.
aboratory analysis. Serum IL-10 concentrations were
easured using a high-sensitivity, quantitative sandwich
nzyme immunoassay (Quantikine HS, R&D Systems Eu-
ope Ltd., Abingdon, United Kingdom). The lower limit of
etection was 0.7 pg/ml, and intra-assay variation among
riplicates was 7.6%. High-sensitivity CRP serum levels
ere measured with an ultrasensitive CRP test (N Latex
RP mono; Behring, Marburg, Germany). The measure-
ent range is 0.02 to 1.1 mg/dl (for 1:20 dilution; higher
oncentrations were determined after appropriate dilution)
ith an intra-assay coefficient of variation of 1.7% to 2.5%
nd an interassay coefficient of variation of 1.7% to 3.6%.
tatistical analysis. Data are expressed as the mean value
SD. Continuous variables were tested for normal distri-
ution with the Kolmogorov-Smirnov test and compared by
ne-way analysis of variance (ANOVA). Categorical vari-
bles were compared by the chi-square test. In the case of
on-normal distribution, the Mann-Whitney U test was
sed. Differences between the group FBF measurements are
resented as the mean value SEM. Differences in forearm
ascular reactivity were examined by repeated measures
NOVA. The FBF responses to ACh and SNP were
alculated as the area under the curve and expressed in
rbitrary units. Linear regression analysis and nonparamet-
ic bivariate correlation (Spearman rank correlation coeffi-
ient) were used to compare FBF responses with CRP or
L-10 serum levels. Multivariate analysis was performed
ith the linear regression model. Serum levels of IL-10 and
RP, as well as low-density lipoprotein (LDL) and high-
ensity lipoprotein (HDL) cholesterol, were included as
ontinuous variables; the clinical characteristics and medi-
ation were included as categorical variables. Statistical
ignificance was assumed, if a null hypothesis could be
ejected at p  0.05. All statistical analyses were performed
ith SPSS for Windows 11.0 (SPSS Inc.).
ESULTS
he clinical characteristics of the patient population are
ummarized in Table 1. Interleukin-10 serum levels ranged
rom 0.17 to 9.63 pg/ml (median 1.64). There was no
orrelation between IL-10 and CRP serum levels (r  0.08,
 0.5). As illustrated in Figure 1, ACh-stimulated FBF
esponses were significantly correlated with IL-10 serum
evels (r  0.31, p  0.02). However, despite ACh-
timulated FBF responses being significantly correlated
ith serum levels of IL-10, FBF responses varied consid-
rably within the lower range of IL-10 serum levels. Because
potential protective function of anti-inflammatory cyto-
ines on endothelial activation may be most prominent in
atients with inflammatory activation, we dichotomized the
atient population into two groups using the median CRP
median 0.61 mg/dl) serum level as a cut-off value. Asllustrated in Table 2, patients with elevated CRP levels
ore frequently presented with unstable angina, had higher
evels of LDL serum cholesterol, and were less likely to
eceive treatment with ACE inhibitors. In patients with low
RP serum levels, IL-10 serum levels did not correlate with
he ACh-stimulated FBF responses (r  0.03, p  NS). In
ontrast, there was a significant positive association between
L-10 serum levels and ACh-stimulated FBF responses in
atients with elevated serum levels of IL-10 (r  0.46, p 
.01). Thus, increased serum levels of the anti-inflammatory
ytokine IL-10 appear to specifically contribute to improved
ndothelial vasodilator function in patients with enhanced
nflammatory activation, as evidenced by augmented CRP
erum levels. The FBF responses to the endothelium-
ndependent dilator SNP did not correlate with IL-10
erum levels in either group (r  0.12, p  0.33). In order
o further corroborate these findings, we stratified our
igure 1. Correlation between and acetylcholine-induced forearm blood
ow (FBF) and interleukin (IL)-10 serum levels responses (calculated as
he area under the curve [AUC]).







(n  32) p Value
ge (yrs) 52.7  5.6 55.1  2.6 NS
ypertension 14 15 NS
iabetes 4 4 NS
ctive smoker 8 9 NS
nstable angina 5 11 0.05
CE inhibitors 23 14 0.05
tatin therapy 29 24 NS
DL cholesterol (mg/dl) 111.4  31.1 131.3  39.2 0.05
DL cholesterol (mg/dl) 45.1  14.3 49.4  13.8 NS
ata are presented as the mean value  SD or number of patients.
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July 7, 2004:44–9 IL-10 and Endothelial Functionatient cohort into four groups according to their median
erum levels of IL-10 and CRP. Patients with low CRP
erum levels had similar ACh-stimulated FBF responses,
egardless of whether IL-10 serum levels were low or
levated (Fig. 2). In contrast, patients with elevated CRP
erum levels exhibited significantly blunted ACh-stimulated
BF responses in the presence of low IL-10 serum levels,
hereas patients with elevated IL-10 serum levels showed
o significant differences in their FBF, as compared with
atients with low CRP serum levels.
Finally, to investigate whether serum levels of IL-10 and
igh-sensitivity CRP are independent predictors of ACh-
timulated FBF responses, we performed a multivariate
nalysis including the classic risk factors for CAD, LDL
nd HDL serum cholesterol levels, clinical symptomatology
stable vs. unstable CAD), ACE inhibitor and statin treat-
ent, as well as CRP and IL-10 serum levels. As illustrated
n Table 3, CRP and IL-10 serum levels remained the only
tatistically significant independent predictors of ACh-
timulated FBF responses in patients with documented
AD. When restricting the multivariate analysis only to the
ariables that were significant in the univariate model, both
erum markers remained independent predictors of ACh-
nduced FBF. Furthermore, as atherosclerotic disease activ-
ty (stable vs. unstable angina) might interfere with serum
evels of IL-10 and CRP, we performed an additional
ultivariate analysis restricted to patients with stable CAD
n 49). This analysis revealed identical results, with IL-10
igure 2. Acetylcholine-induced dose-response curves for forearm blood
ow (FBF) calculated as the percent increase in FBF from baseline in
atients with C-reactive protein (CRP) less than the median value
triangles) and patients with CRP greater than or equal to the median
alue (circles). Solid symbols represent patients with IL-10 serum levels
ess than the median, and open symbols represent patients with IL-10
erum levels greater than or equal to the median. Data are expressed as the
ean value  SEM.p  0.016) and CRP serum levels (p  0.030) remaining ohe only independent predictors of ACh-stimulated FBF
esponses in patients with stable CAD.
ISCUSSION
he results of the present study demonstrate that serum
evels of the anti-inflammatory cytokine IL-10 are indepen-
ent predictors of the endothelium-mediated vasodilator
esponse of the forearm circulation in patients with CAD.
ost importantly, elevated IL-10 serum levels counteract
he impairment in systemic endothelial function associated
ith increased CRP serum levels. These data, for the first
ime, demonstrate that the balance between pro- and
nti-inflammatory cytokines is a major determinant of
ndothelial function in patients with CAD.
Interleukin-10, which is predominantly secreted by acti-
ated monocytes, macrophages, and lymphocytes (16), has
ultifaceted anti-inflammatory properties, including inhi-
ition of the prototypic inflammatory transcription factor
uclear factor kappa B, leading to suppressed cytokine
roduction (17), inhibition of matrix-degrading metallopro-
einases (18), reduction of tissue factor expression (19),
nhibition of apoptosis of macrophages and monocytes after
nfection (20), and promotion of the phenotypic switch of
ymphocytes into the Th2 phenotype (21). Most notably
ith respect to the present study, IL-10 was experimentally
hown to protect endothelial function after an acute inflam-
atory stimulus by limiting local increases in superoxide
eneration within the vascular wall (15). Likewise, IL-10
as experimentally shown to impede endothelial dysfunc-
ion during development of diabetes via reducing the pro-
uction of superoxide anions (22). Enhanced superoxide
nion secretion not only directly scavenges nitric oxide
NO) but also oxidatively modifies cofactors of the nitric
able 3. Multivariate Analysis, Including Risk Factors for
oronary Artery Disease and Clinical Presentation for









L-10 (mg/dl) 0.013 0.99 0.33 0.010
RP (mg/dl) 0.002 3.52 0.37 0.012
DL cholesterol
(mg/dl)
0.49 0.06 0.11 0.37
DL cholesterol
(mg/dl)
0.75 0.14 0.08 0.54
ypertension 0.79 1.05 0.05 0.73
iabetes 0.43 4.32 0.14 0.28
urrent smoking 0.82 2.30 0.01 0.92
nstable angina 0.81 1.90 0.09 0.53
CE inhibitors 0.37 0.68 0.01 0.84
tatins 0.91 1.11 0.02 0.58
djusted R2  0.27. Significance for the model (analysis of variance): p  0.05.
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IL-10 and Endothelial Function July 7, 2004:44–9ctivity, resulting in an impaired endothelium dependent
asodilation (23,24). Indeed, in the present study, the
rotective effects of IL-10 serum levels on endothelial
asodilator function were most prominent in patients with
levated CRP serum levels, which has been shown to
irectly decrease endothelial NOS expression and increase
uperoxide anion production in endothelial cells (25–27).
hus, taken together, elevated serum levels of IL-10 might
e associated with reduced superoxide anion generation of
he activated endothelium in patients with low-grade
hronic inflammation of the vascular wall, resulting in
mproved NO bioavailability and, consequently, increased
asodilator responses to the endothelium-dependent medi-
tor ACh.
Given that endothelial vasodilator function represents a
unctional read-out of a variety of noxae, as well as protec-
ive mediators acting on the vascular wall, the extensive
edical treatment of our patient population might have an
mpact on the results of the present study by unmasking the
ffects of IL-10 and CRP. Because the cross-sectional
esign of our study included patients with long-term med-
cal therapy known to modulate endothelial function in the
resence of CAD (e.g., statins and ACE inhibitors), we
annot address the question of whether statin or ACE
nhibitor treatment alters the association between endothe-
ial vasodilator function and inflammatory markers. Like-
ise, because women were excluded, we cannot comment
n a potential interference with sex hormones. Finally,
lthough our multivariate analysis included all previously
stablished major determinants of endothelial function in
atients with CAD, we cannot exclude that subtle differ-
nces in risk factor profile or effective treatment might have
one unnoticed. However, regardless of these potential
imitations, the results of the present study, obtained in a
eal-world scenario of patients extensively treated with
spirin, beta-blockers, statins, and ACE inhibitors, support
he concept of further enhancement of an anti-
nflammatory mechanism in order to improve endothelial
asodilator function, especially in patients with elevated
RP serum levels.
Heitzer et al. (11) have previously shown that the
mprovement in systemic endothelial vasodilator function by
cutely scavenging reactive oxygen species, using intra-
rterial infusion of vitamin C, is a major determinant of
therosclerotic disease progression in patients at risk. The
ata of the present study now further support the concept
hat the balance between pro- and anti-inflammatory cyto-
ines is a major determinant of endothelial vasodilator
unction in patients with CAD. Moreover, our previous
tudies have demonstrated that elevated IL-10 serum levels
brogated the increased risk of death and recurrence of
yocardial infarction associated with elevated CRP levels
nd independently predicted the clinical outcome in patients
ith ACS (5), thereby extending a previous report suggest-ng an association between elevated IL-10 serum levels andecreased risk of coronary events in patients with unstable
ngina (28). Most importantly, recent experimental studies
ould demonstrate that systemic or local IL-10 gene transfer
ot only attenuates atherogenesis (16,29,30) but also mod-
lates processes associated with lesion progression (21).
ecause endothelial vasodilator function integrates the risk
actor load on the vascular wall (8) and represents an
stablished surrogate marker for atherosclerotic disease pro-
ression in patients with CAD (10) or at risk of developing
therosclerosis (9,11,31), it will be important to disclose
hether therapeutic interventions that increase circulating
L-10 levels may improve endothelial vasodilator function
n patients with CAD and ongoing elevated inflammatory
ctivity.
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